The global colorectal cancer therapeutics market was valued at USD 9.26 billion in 2018 and is expected to grow significantly, reaching approximately USD 26.49 billion by 2032. This growth reflects a compound annual growth rate (CAGR) of 7.8% over the forecast period. In 2018, North America led the market, accounting for 44.6% of the total global share.
